Having completed the final investment of the Approved EIS Fund 09 in December 2009 I am now able to reflect with pleasure on the diversification we have achieved with this Fund.

The portfolio is well diversified across the healthcare and life sciences sectors with one beauty company, three related to cancer treatments, one to cardiovascular disease and one to orthopaedic/dental. There are two retail products, one biotech company and four medical device companies, with 2 products ready to launch, one awaiting regulatory approval and a fourth in development.

Co-investors have included Takeda Pharmaceuticals, Imperial College, Esmee Fairburn Foundation, Finance Wales and Scottish Enterprise.

We will be closing our 2010 Approved EIS Fund at the end of this tax year and there are already several exciting investment opportunities being explored and I am looking forward to another year of interesting and worthwhile investing.